Solid Biosciences Inc.

Solid Biosciences Inc.

Solid Biosciences Inc., headquartered in Novato, California with additional offices in Charlestown, Massachusetts, is a publicly traded biotechnology company focused on genetic medicines. The firm was founded to develop therapies for rare neuromuscular and cardiac diseases, operating as a drug developer rather than an investment vehicle. The company's pipeline centers on gene therapy candidates, including SGT-003 for Duchenne muscular dystrophy (DMD) and preclinical programs for other neuromuscular and cardiac conditions. Solid Biosciences does not manage third-party capital or function as a family office; its funding derives from public equity markets, collaborations, and grants. The firm engages in research and development across gene editing, vector engineering, and manufacturing. As of 2025, Solid Biosciences employs a team of scientists and clinical development staff primarily in the United States. The firm has not disclosed total professionals or assets under management. In October 2023, the company announced positive interim clinical data for SGT-003 in DMD patients (per Solid Biosciences press release, October 2023). The firm's structural differentiator is its status as a publicly traded gene therapy company, distinct from traditional family offices or asset managers. Its focus on rare diseases with high unmet need positions it within a niche of precision medicine, but it operates under standard biotech corporate governance with shareholder accountability.